MedInCell Stock Jumps 5.51% Defying a Downward CAC 40
The Montpellier-based biotech's stock marks one of the strongest gains in the biotech sector on Euronext Paris in mid-afternoon trading. At 24.12 euros, MedInCell rebounds sharply after several sessions of consolidation, despite a generally bearish market environment, with the CAC 40 down 0.57% during the session.
A Technical Rebound Above Short-Term Moving Averages
After slipping to 22.86 euros on Tuesday, the stock regained 5.51% and moved above several key thresholds monitored by traders. It crossed the 50-day moving average (22.93 euros) and the MM20 (23.33 euros), and is now approaching the 200-day moving average set at 24.03 euros, nearly touching this level during the session. The RSI is at 49, in a neutral zone indicating neither overbought nor oversold conditions, while the MACD remains close to its signal line at 0.53, with a zero histogram. Regarding boundaries, the Bollinger Bands frame the stock between 21.31 euros and 25.35 euros, with the price now in the upper 70% of this range. The technical resistance identified at 25.12 euros is the next reference level, while the support at 20.24 euros remains distant. With a monthly volatility of 14.77 and a beta of 0.19, the stock remains weakly correlated with the general movements of the stock market.
A Solid Yearly Trajectory as Annual Results Approach
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Over the past year, the stock has shown a gain of 60.91%, a performance that contrasts with a nearly flat quarterly performance (+0.42% over three months) and a weekly decline of 1.79%. This configuration illustrates a consolidation phase following the rally that began in 2025, with several euros of fluctuations since the beginning of April, as evidenced by the sessions on April 8 (+5.72%) and April 15 (-2.07%). The financial calendar now provides concrete visibility for shareholders: the company will publish its annual results for the 2025-2026 fiscal year on June 16, 2026, followed by the general meeting scheduled for September 10, 2026. In the European biotech sector, immediate peers are moving in the opposite direction during the session, with Argenx down 1.62% and Abivax down 1.73%, highlighting the idiosyncratic nature of the stock's movement. The next technical test will occur at the resistance level of 25.12 euros, whose crossing would validate the end of the consolidation phase observed over the past three months.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
